Daehan New Pharm Co. Ltd Cash Flow-to-Debt Ratio
Daehan New Pharm Co. Ltd cash flow-to-debt ratio. Daehan New Pharm Co. Ltd (054670) has a Cash Flow-to-Debt Ratio of 0.04x as of September 2025, meaning its operating cash flow of ₩4.43 Billion could theoretically repay 0% of its total liabilities (₩122.10 Billion) in one year. Check 054670 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Daehan New Pharm Co. Ltd (2014–2024)
Cash flow-to-debt ratio of Daehan New Pharm Co. Ltd from 2014 to 2024. Historical debt coverage capacity for Daehan New Pharm Co. Ltd across 11 annual periods. Check Daehan New Pharm Co. Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Daehan New Pharm Co. Ltd Cash Flow-to-Debt Ratio by Year (2014–2024)
Daehan New Pharm Co. Ltd cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for Daehan New Pharm Co. Ltd. For the full cash flow conversion analysis, see 054670 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.20x | ₩18.95 Billion | ₩95.85 Billion | ▲ +6.3% |
| 2023 | 0.19x | ₩12.57 Billion | ₩67.57 Billion | ▼ -13.4% |
| 2022 | 0.21x | ₩14.25 Billion | ₩66.40 Billion | ▼ -2.7% |
| 2021 | 0.22x | ₩16.58 Billion | ₩75.18 Billion | ▲ +23.7% |
| 2020 | 0.18x | ₩13.55 Billion | ₩75.95 Billion | ▼ -47.9% |
| 2019 | 0.34x | ₩22.89 Billion | ₩66.84 Billion | ▲ +9.8% |
| 2018 | 0.31x | ₩20.47 Billion | ₩65.66 Billion | ▲ +1001.6% |
| 2017 | -0.03x | ₩-2.42 Billion | ₩70.09 Billion | ▼ -123.5% |
| 2016 | 0.15x | ₩8.75 Billion | ₩59.52 Billion | ▲ +4.4% |
| 2015 | 0.14x | ₩7.80 Billion | ₩55.43 Billion | ▼ -20.5% |
| 2014 | 0.18x | ₩10.02 Billion | ₩56.58 Billion | — |